Many patients with Graves' ophthalmopathy (GO) suffer from dry eye syndrome (DES), and this is one of the most common reasons of eye discomfort in patients with GO. The prevalence of DES in patients with GO is significantly higher than normal subjects. The ocular surface changes involving changes in tears, cornea, conjunctiva and glands occur in GO patients. However, the mechanism of how DES occurs in GO still remains unclear. In this review, the ocular surface changes were illustrated and analyzed the reasons for high prevalence of DES in GO patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025155 | PMC |
| http://dx.doi.org/10.18240/ijo.2021.04.20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A masked study to differentiate in vivo confocal microscopic features of Pythium insidiosum and fungal filaments.
Ocul Surf
March 2025
Jhaveri Microbiology Centre, LV Prasad Eye Institute, Hyderabad, India.
Purpose: To describe in vivo confocal microscopic features of Pythium insidiosum in patients with Pythium keratitis and compare with those observed in fungal keratitis.
Method: We collected in vivo confocal images of the cornea from patients with microbiologically confirmed Pythium and fungal keratitis, analysing five putative distinguishing features: filament width (broad or thin), granularity within the filament (present or absent), filament continuity or traceability, the presence or absence of loops, and the double track sign. Three masked observers were shown images with concealed identities and tasked with detecting Pythium filaments.
Function of levator palpebrae superioris in dry eye disease.
Int Ophthalmol
March 2025
Department of Ophthalmology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, #222 Banpo-Daero, Seocho-Gu, Seoul, 06591, Korea.
Purpose: To evaluate the effect of levator palpebrae superioris in patients with dry eye disease.
Methods: 168 eyes of 84 patients (group 1 = fair levator function ≤ 9 mm, 78 eyes; group 2 = good levator function > 9 mm, 90 eyes) were retrospectively enrolled. Levator function test, Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, meibography, meibum quality and expressibility scores, tear meniscus height, and partial blinking rate (PBR) were examined.
Ocular symptoms in COVID-19 patients with a history of hospitalization in the first pandemic wave in Styria, Austria.
Front Ophthalmol (Lausanne)
February 2025
Department of Ophthalmology, Medical University Graz, Graz, Austria.
Purpose: Our study aimed to investigate the prevalence and timing of ocular surface manifestations in hospitalized COVID-19 patients, providing insights into the occurrence of eye involvement before, during, or after the illness. This study contributes to understanding the extent of ocular involvement in COVID-19, which has been suggested to occur due to potential viral entry through the eyes.
Methods: 451 confirmed COVID-19 patients had a history of hospitalization in Styria, Austria.
Identification of a non-inhibitory aptameric ligand to CRL2 E3 ligase for targeted protein degradation.
Nat Commun
March 2025
Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education); Key Laboratory of Immune Microenvironment and Disease (Ministry of Education); The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Biochemistry and Molecular Biology, Tianjin Medical University; Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
As a crucial element of proteolysis targeting chimeras (PROTACs), the choice of E3 ubiquitin ligase significantly influences degradation efficacy and selectivity. However, the available arsenal of E3 ligases for PROTAC development remains underexplored, severely limiting the scope of targeted protein degradation. In this study, we identify a non-inhibitory aptamer targeting ZYG11B, a substrate receptor of the Cullin 2-RING ligase complex, as an E3 warhead for targeted protein degradation.
View Article and Find Full Text PDFCan Sustained Suppression of VEGF be Achieved by Topical Ocular Delivery?
Am J Ophthalmol
March 2025
The Center for Nanomedicine, Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Departments of Pharmacology and Molecular Sciences, Biomedical Engineering, Gynecology and Obstetrics, Oncology, and Division of Infectious Diseases Johns Hopkins University School of Medicine, Baltimore, MD, 21231. Electronic address:
Purpose: Less invasive options for treating pathological blood vessel growth and leakage in the eye are an attractive option pursued by many in the commercial and academic spaces alike. However, achieving safe and effective therapeutic delivery to the posterior segment with a topical eye drop has proven very challenging. In this review, we describe past and ongoing clinical efforts to develop topical ocular therapies for the clinical management of vascular endothelial growth factor (VEGF)-dependent retinal vascular diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!